Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Coverage · Pharmacy · NJ · Rheumatology, Nephrology, Internal Medicine +1 moreLow impact

MA08.057d, Belimumab (Benlysta®) for Intravenous Use

Effective date
Not stated in the notice
Identified
Jul 23, 2026

Summary

Independence Blue Cross reissued Medicare Advantage Policy MA08.057d on 07/22/2026 to communicate its continuing position on belimumab (Benlysta) for intravenous use in systemic lupus erythematosus and lupus nephritis. A guideline restriction on subcutaneous dosing for pediatric patients was removed to align with current FDA labeling. Coverage criteria for SLE and lupus nephritis remain unchanged for patients age 5 and older meeting specified clinical requirements.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01No immediate billing workflow changes required.
02This is a reissue of existing policy with no substantive changes to coverage criteria or billing requirements.
03Billing team should note that the policy continues to apply to New Jersey Medicare Advantage lines of business (effective 01/01/2024) and covers belimumab (J0490) only when medical necessity criteria are met for SLE or lupus nephritis in patients age 5 and older.
04Continue to require appropriate documentation of active disease, positive autoantibody testing, and concurrent standard treatment before processing claims.
05No updates to billing software, prior authorization processes, or claim submission procedures are necessary.

Codes mentioned

J0490M32.0M32.10M32.11M32.12M32.13M32.14M32.15M32.19M32.8M32.9

Original notice

MA08.057d, Belimumab (Benlysta®) for Intravenous Use
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.140c, Anifrolumab-fnia (Saphnelo®)LowEffective Jun 17, 2024 · PharmacyMA08.140c, Anifrolumab-fnia (Saphnelo®)LowNo effective date · Pharmacy08.01.82c, Anifrolumab-fnia (Saphnelo®)LowEffective Jun 17, 2024 · Pharmacy08.01.82c, Anifrolumab-fnia (Saphnelo®)LowNo effective date · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesNJ policy changesRheumatologyNephrologyInternal MedicinePediatricsCode J0490Code M32.0Code M32.10Code M32.11Code M32.12Code M32.13Code M32.14Code M32.15Code M32.19Code M32.8Code M32.9

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account